No More Free Drug Samples? by Chimonas, Susan & Kassirer, Jerome P.
Essay
No More Free Drug Samples?
Susan Chimonas
1*, Jerome P. Kassirer
2
1Center on Medicine as a Profession, Columbia University, New York, New York, United States of America, 2Tufts University School of Medicine, Boston, Massachusetts,
United States of America
Everybody likes something free, and
free prescription drug samples are no
exception. Patients love to receive them,
and doctors feel good about handing them
out. The practice of providing free drug
samples is based on the tacit assumption
that ‘‘sampling’’ does much more good
than harm. In two separate news releases
within the past year by the Pharmaceutical
Research and Manufacturers of America
(PhRMA), the trade organization that
represents the country’s largest and lead-
ing drug companies, a senior vice presi-
dent claimed that free samples improve
patient care, foster appropriate medication
use, and help millions of financially
struggling patients. He averred further
that samples benefit physicians by expos-
ing them to new treatment options [1,2].
In this essay, we question the assumption
that good trumps harm when prescription
drugs are provided free to practicing
doctors. We argue that ‘‘sampling’’ is not
effective in improving drug access for the
indigent, does not promote rational drug
use, and raises the cost of care.
Who Actually Receives the
Samples?
Studies show who receives the free
drugs. A nationally representative survey
in the United States found that fewer than
one-third of all sample recipients were low
income (defined as less than 200% of the
poverty line); by contrast, those in the
highest income category were most likely
to have received free samples. Moreover,
low-income uninsured patients were less
likely to receive free samples than those
who had continuous health insurance [3].
These findings are supported by an
analysis of a large database of individuals
who had received at least one prescription
drug in a given year. In this study, indigent
patients were less likely to receive samples
than those classified as non-poor [4].
Often samples never reach their intend-
ed audience. Many samples are appropri-
ated by physicians for personal or family
use or end up in an ‘‘unknown destina-
tion’’ [5,6]. And in one study, nearly half
of pharmaceutical representatives sur-
veyed reported using samples themselves
or giving them to their friends and
relatives [7]. These studies indicate that
samples often reach the wrong people and
are frequently misused.
Quality of Care
Samples can have negative consequenc-
es. When low-income patients are given a
‘‘starter pack’’ of samples and a prescrip-
tion to fill for the remaining period of
treatment, they might not be able to afford
the cost of the extension, thus leading to
discontinuity of treatment. In pharmacies,
drugs are labeled, catalogued, stored, and
carefully dispensed. In drugstores, phar-
macists often identify potentially harmful
drug interactions, intercept inadvertent
medication errors, and offer a patient-
friendly printout of instructions. In doc-
tors’ offices, however, detailed patient
education regarding sample use rarely
occurs, and when it does, it usually lacks
information about drug interactions or
instructions on how the drug should be
taken [8]. Given the lack of oversight by a
skilled pharmacist, there is a risk that
expiration dates could be overlooked.
Moreover, if distribution is inadequately
documented in patients’ records, some
people who receive samples in doctors’
offices may not be notified or told to
discontinue the medication in the event of
a product recall or the emergence of new
drug complications.
The samples that drug representatives
offer are almost never time-worn and well-
tested drugs, nearly never generics, and
usually comprise the newest agents on the
market. As such, they expose patients to
risks not yet identified in clinical trials.
The experience with Vioxx is a case in
point. By 2002, only three years after
Vioxx was introduced, it became the most
widely distributed sample [3], and two
years later the drug was withdrawn from
the market because of an excess risk of
myocardial infarctions and strokes [9].
Needless to say, Vioxx was not the only
drug given extensively as samples and later
found to enhance risk. Samples given to
pediatric patients have similarly been
associated with notable safety concerns.
In 2004, four of the 15 medications most
frequently given as samples to children in
the US received new or revised ‘‘black
box’’ warnings from the US Food and
Drug Administration within two years of
approval [10]. Finally, patients may not be
the only ones at risk from distribution of
free samples. Physicians who offer samples
to patients and fail to supply appropriate
cautions and warnings about the use of
these drugs may be subject to liability,
along with the company that promoted the
drug [11].
Charity and Education, or
Marketing?
It is difficult to escape the conclusion that
the prime motivation behind the provision
of free samples is marketing. Samples have a
major influence on physicians’ prescribing
habits [12–15]. Samples are one of the most
effective ways sales representatives get their
foot in the door to pitch their companies’
products. The technique is effective; the
availability of samples is associated with
rapid prescription of the new drug [15]. In
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were more likely than their counterparts
without samples to prescribe heavily adver-
tised products and less likely to suggest an
over-the-counter alternative [16]. And a
survey based on self-reported physician
judgments suggests that the availability of
samples might even influence physicians to
prescribe drugs that would not otherwise be
their top choice [17].
Although the provenance of the casual
comments in message boards on Web sites
for pharmaceutical sales representatives is
uncertain, many of the entries reflect the
impressive influence of sampling. Some
comments are: ‘‘Without samples the
available access will be slim to none! The
ability to influence doctors will be nil’’
[18]. Another warned, ‘‘If [the companies]
are not giving you samples and expecting
you to gain access to docs with just a
reprint and a detail piece you may be in
trouble’’ [19]. As a physician explained to
The New York Times, ‘‘They are not
bringing us samples of things we
need…They are bringing us things they
want us to know about’’ [20].
Health Care Costs
Samples are not effective in lowering
patients’ costs. Indeed, evidence shows
that patients who received free samples
had higher out-of-pocket costs than their
counterparts who were not given free
samples [21]. Samples raise the cost of
health care, as companies recoup market-
ing costs through higher prices and
increased sales volume. Samples constitute
an enormous promotional outlay of phar-
maceutical companies. Between 1996 and
2000, they accounted for slightly more
than half of the total promotional dollars
spent by industry [22]. Although there is
controversy about how best to tally the
amount of money the pharmaceutical
industry spends on free samples, a recent
analysis of 2004 figures sets the retail value
of samples at approximately 16 billion US
dollars [23]. The retail value of free
samples has risen steadily, doubling be-
tween 1999 and 2003 [24] (Figure 1).
Sample distribution often intensifies dur-
ing new drug launches, or when a product
is withdrawn from the market and com-
petitors scramble to fill the vacuum [25].
Samples raise health care costs by
promoting the use of expensive products.
In the US, prescription costs grew 5-fold
from 1990 to 2006 [26] and are said to be
approaching US$200 billion annually
[27]. A substantial fraction of the increase
is attributed to a growing reliance on
expensive, brand-name medications [28]
(Figure 2). One analysis several years ago
showed that in a single year, the 50 most
heavily marketed drugs accounted for
nearly half of the increase in retail
spending on prescription drugs (the other
9,850 drugs made up the remaining sum)
[29]. These are the very products patients
are mostly likely to receive as samples.
Input from Professional
Organizations
A few years ago, a widely acclaimed
report on medical errors from the Institute
of Medicine took a hard look at free
samples. It noted the growing unease in
the medical profession about the way
samples are distributed, the lack of docu-
mentation of medication use, and the by-
passing of drug-interaction checks and
counseling [30]. Nonetheless, pharmaceu-
tical companies clearly believe that sam-
pling is an effective sales strategy or they
would not spend so much of their
advertising budget on it, and they continue
to distribute samples to individual physi-
cians despite opposition against the prac-
tice from a number of groups. The
American Society of Health-System Phar-
macists, a 35,000-member national pro-
fessional association of pharmacists in
hospitals and health systems, has opposed
the use of samples [31]. The Joint
Commission, which accredits and certifies
more than 15,000 health care organiza-
tions and programs in the US, requires
that all stages of the medication use
process—selection, storage, ordering, dis-
pensing, administration, and monitor-
ing—must be appropriately integrated
into a comprehensive medication manage-
ment system, and this policy applies across
the board (K. Powers, personal communi-
cation, January 23, 2009). In fact, the
Commission reportedly identified lax doc-
umentation of drug samples as one of the
top ten abuses of hospital-practice stan-
dards [32]. The Association of American
Medical Colleges and the Association of
Faculties of Medicine of Canada recom-
mend distribution of samples only under
carefully controlled conditions—namely,
by setting up centralized systems at
medical centers for accepting and distrib-
uting the drugs [33,34]. These policies are
part of a comprehensive approach in
North America to reduce the influence of
the pharmaceutical industry on the med-
ical profession.
Alternatives to Samples
‘‘Sampling’’ is predominately an Amer-
ican problem. Many European countries
provide universal health coverage, includ-
ing prescription drugs. They negotiate
with pharmaceutical companies on prices,
formally assess the benefits and risks of
new drugs, and decide which drugs they
will pay for. Under such circumstances,
providing new drugs free to doctors has
little marketing potential. Discussions
abounded at the beginning of 2009 about
incorporating many of the health system
attributes of European countries into the
American health care system, but given
the impressive power of lobbyists, many
observers doubt that such comprehensive
reform will take place. Assuming that the
US population will not be covered by a
comprehensive prescription drug benefit,
alternatives to samples must be available.
Many generic and over-the-counter med-
ications are highly effective and have been
proven safe by years on the market. They
also cost a fraction of the price. RxOu-
treach.com provides generic drugs to
patients at or below 250% of the Federal
Poverty Level, at a cost of US$20–US$40
for a 90-day supply [35]. Wal-Mart
Figure 1. Retail value of US samples, in billions of dollars.
doi:10.1371/journal.pmed.1000074.g001
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hundreds of generic drugs for only US$4
per month, and many of its competitors
are expected to follow suit [36].
Most pharmaceutical companies offer
‘‘patient assistance programs’’ that provide
free or low-cost medications to those who
cannot afford them. New resources in the
US, including NeedyMeds.com and RxAs-
sist.org, have made information about
these patient assistance programs more
accessible. Although some patients have
found these programs cumbersome, time-
consuming, and difficult to navigate, many
clinics help patients facilitate their appli-
cations.
Many American and Canadian hospi-
tals and medical centers have begun to
replace samples with voucher systems. At
the University of Michigan, the University
of Pennsylvania, the University of Wis-
consin, and the Puget Sound Health
Alliance, for example, physicians give
patients drug vouchers, which are then
filled without charge by the hospital
pharmacy [37]. This system allows pa-
tients to leave the hospital with a trial
supply of medication in hand while
ensuring adequate documentation and
tracking. Yet some US institutions, appre-
ciating the cost implications, have taken a
bold step and have barred their physicians
from giving free samples or vouchers to
patients [38,39].
A Call for Change
It is unrealistic to expect pharmaceuti-
cal companies to give up one of their most
potent marketing techniques voluntarily.
Thus, if we are convinced that using free
samples is counterproductive in terms of
the quality and cost of care, only the
medical profession can seek a halt to the
practice. The voucher approach is an
improvement over our current method of
sample distribution, but we favor having
our institutions eliminate the use of
samples. We call on medical societies,
including the American Medical Associa-
tion, to educate their practitioner mem-
bers about alternatives to free samples and
to re-examine their guidelines on accep-
tance of samples.
The tradition of physicians dispensing
samples has many serious disadvantages
and is as anachronistic as bloodletting and
high colonic irrigations. As the profession
begins to slowly extract itself from the
influential grip of industry, it must also
deal with the undue influence of free
samples.
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